Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected
United States Eli Lilly European Society Of Medical Oncology European Commission Drug Administration Head Of Development Unit
Source: finanznachrichten.de